Supplementary Table 1. Study characteristics and association between OC use and breast cancer incidence

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Case-control							
Shapiro, 2000 (1)	**Black or Colored women aged 20–54 yr in Cape Town** Cases: 484 invasive breast cancer, hospital Controls: 1625, hospital Recruitment period: 1994–1997	1.2	1.0 to 1.5	Age, sex, injectable progesterone use, ethnicity	South Africa	Fair	1
Van Hoften, 2000 (2)	**Women aged 41–52 yr in Doorlopend Onderzoek Morbiditeit/Mortaliteit Cohort Study** Cases: 309 incident breast cancer, breast cancer screening program Controls: 610 cohort members Recruitment period: 1982–1984	1.24	0.96 to 1.78	Age, parity, menopausal status, age at menarche, smoking, marital status, education, age at first delivery, maternal history of breast cancer	Netherlands	Good	1
Gomes, 2001 (3)	**Hospital patients in Belo Horizonte (age NR)** Cases: 280 breast cancer, hospital Controls: 569 outpatients or gynecology inpatients Recruitment period: 1978–1987	1.93	1.19 to 3.11	Parity, menopausal status, family history, occupation (housewife, housekeeper, other) irregular menstrual cycles, and possibly other (hard to tell)	Brazil	Poor	1

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Moorman, 2001 (4)	**Women aged 20–74 yr in Carolina Breast Cancer Study** *White <50 yr* Cases: 328 invasive breast cancer, registry Controls: 236, DMV or Medicare lists	1.27	0.76 to 2.21	Age, family history, age at menarche, breastfeeding , age at first pregnancy, age at menopause	U.S.	Fair	1
	African American <50 yr Cases: 175 invasive breast cancer, registry Controls: 171, DMV or Medicare lists	1.41	0.82 to 2.41				
	White ≥50 yr Cases: 195 invasive breast cancer, registry Controls: 221, DMV or Medicare lists	0.95	0.59 to 1.53				
	African American ≥50 yr Cases: 160 invasive breast cancer, registry Controls: 161, DMV or Medicare lists	0.90	0.51 to 1.57				
	Recruitment period: 1993–1996						
Heimdal, 2002 (5)	**Women aged 40–60 yr from breast cancer families in a cancer family clinic** Cases: 380 breast cancer Controls: 1043	0.90	0.68 to 1.19	Parity, age at menarche, BRCA1 mutation status	Norway	Fair	2
	Recruitment period: 1999						
Marchbanks, 2002 (6)	**Women aged 35–64 yr in Women's Contraceptive and Reproductive Experiences (CARE) Study** Cases: 4575 breast cancer, SEER registries Controls: 4682, community	0.9	0.80 to 1.01	Age, race, parity, menopausal status, BMI, family history, age at menarche, study site, age at menopause, age at first term pregnancy, hormone replacement therapy	U.S.	Good	1
	Recruitment period: 1994–1998						

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Narod, 2002 (7)	**Known carriers of BRCA1 or BRCA2 mutations** *BRCA1 carriers* Cases: 981 breast cancer, research studies Controls: 981, research studies *BRCA2 carriers* Cases: 330 breast cancer, research studies Controls: 330, research studies Mean age of cases at diagnosis: 39.1 yr (SD 8.1) Recruitment period: 1977–2001	 1.20 0.94	 1.02 to 1.40 0.72 to 1.24	Race, parity	52 centers in 11 countries	Fair	3
Tryggvadottir, 2002 (8)	**All Icelandic women diagnosed with first invasive breast cancer from 1979–1995** Cases: 1120, registry Controls: 10,537, registry Recruitment period: 1979–1995	NR	NR	NA	Iceland	Good	5
Althuis, 2003 (9)	**Premenopausal women aged 20–54 yr** Cases: 265 breast cancer, <35 yr Controls: 280 community controls, <35 yr Cases: 1214 breast cancer, 35–44 yr Controls: 1033 community controls, 35–44 yr Cases: 271 breast cancer, 45–54 yr Controls: 244 community controls, 45–54 yr Recruitment period: 1990–1992	 0.73 1.13 2.03	 0.5 to 1.1 0.9 to 1.4 1.3 to 3.1	Age, race, BMI, age at menarche, study site, number of mammograms within 5 yr prior to diagnosis, recent oral contraceptive use, a combination variable for age at birth and number of full-term births, family history of breast cancer, alcohol consumption	U.S.	Good	1

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Althuis, 2003 (10)	**Women aged 20–54 yr in 5 metropolitan areas** Cases: 1640 invasive or *in situ* breast cancer, registries Controls: 1492 no breast cancer, community Recruitment period: 1990–1992	NR	NR	NA	U.S.	Fair	4
Newcomer, 2003 (11)	**Women <75 yr in Collaborative Breast Cancer Study** Cases: 5510 breast cancer, registries Controls: 9311, community Note: ductal cancer only (lobular cancer cases excluded) Recruitment period: NR	1.00	0.90 to 1.11	Age, race, BMI, family history, type of and age at menopause, state, education, alcohol	U.S.	Fair	10
Norman, 2003 (12)	**Women aged 35–64 yr in Women's Contraceptive and Reproductive Experiences (CARE) Study** Cases: 1847 breast cancer, SEER registries Controls: 1932, community Recruitment period: 1994–1998	NR	NR	NA	U.S.	Fair	5
Suter, 2003 (13)	**Women <45 yr in Western Washington** Cases: 524 breast cancer, SEER registry Controls: 461, community Recruitment period: 1990–1992	1.3	0.9 to 1.8	Age	U.S.	Fair	1

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Wrensch, 2003 (14)	**Residents of Marin County, California** *All subjects* Cases: 285, registry Controls: 286, community	0.43	0.26 to 0.72	Age, residence at birth	U.S.	Good	1
	Age <50 Cases: 201, registry Controls: 201, community	0.41	0.22 to 0.75				
	Age >50 Cases: 84, registry Controls: 85, community	0.15	0.03 to 0.65				
	Recruitment period: 1997–1999						
Fowke, 2004 (15)	**Women aged 25–70 yr in Shanghai Breast Cancer Study** *Premenopausal* Cases: 103 breast cancer, hospitals and registry Controls:103, resident registry	0.92	0.67 to 1.26	Age, parity, BMI, age at menarche, education, fibroadenoma history, leisure time activity, age at first live birth	China	Fair	9
	Postmenopausal Cases: 110 breast cancer, hospitals and registry Controls: 127, resident registry	0.96	0.70 to 1.32				
	Recruitment period: 1996–1998						
Jernstrom, 2005 (16)	**Women <40 yr in South Swedish Health Care Region** Cases: 245 breast cancer, registry Controls: 735, community	1.65	0.95 to 2.87	Parity, family history, age at menarche, smoking	Sweden	Fair	4
	Recruitment period: 1990–1995						

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Milne, 2005 (17)	**Women <40 yr in San Francisco, Ontario, Melbourne, and Sydney** *Cases with BRCA1 mutation* Cases: 47 breast cancer, registries Controls: 815, community	0.22	0.10 to 0.49	Age, parity, family history, age at menarche, study location/period, education, marital status, country of birth	U.S., Canada, Australia	Good	4
	Cases with BRCA2 mutation Cases: 36 breast cancer, regional registries Controls: 815, community	1.02	0.34 to 3.09				
	Cases with neither BRCA1 or 2 mutations Cases: 1073 breast cancer, registries Controls: 815, community	0.93	0.69 to 1.24				
	Recruitment period: 1995–1998						
Gronwald, 2006 (18)	**BRCA1 carriers, Hereditary Cancer Center (age NR)** Cases: 348 breast cancer, cancer center Controls: 348, cancer center	0.80	0.50 to 1.20	NR	Poland	Fair	3
	Recruitment period: NR						
Haile, 2006 (19)	**White women <40 yr BRCA1 or BRCA2 carriers** *BRCA1 carriers (cases and controls)* Cases: 111 breast cancer, registries Controls: 185, registries	0.64	0.35 to 1.16	Age, parity, family history, study site	U.S., Canada, Australia	Good	3
	BRCA2 carriers (cases and controls) Cases: 71 breast cancer, registries Controls, 94, registries	1.29	0.61 to 2.76				
	Recruitment period: NR						

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Ma, 2006 (20)	**Women aged 35–64 yr in Women's Contraceptive and Reproductive Experiences (CARE) Study** Cases: 1725 breast cancer, SEER registries Controls: 440, community Recruitment period: 1994–1998	NR	NR	NA	U.S.	Good	5
Rosenberg, 2006 (21)	**Extension of a case-control study among Swedish residents aged 50–74 yr** Cases: 2289 ductal, lobular, or tubular cancer, registries Controls: 3065, population registry Recruitment period: 1993–1995	NR	NR	NA	Sweden	Fair	5
Faheem, 2007 (22)	**Hospital patients in Islamabad** Cases: 150,breast cancer, hospital Controls: 159, community Mean age of cases: 42 yr (SD 12) Recruitment period: 2005	NR	NR	NA	Pakistan	Poor	5
Folger, 2007 (23)	**Women aged 35–64 yr with history of short-term OC use, Women's CARE study** *Premenopausal* Cases: 497 breast cancer, SEER registries Controls: 456, community *Postmenopausal* Cases: 729 breast cancer, SEER registries Controls: 707, community Recruitment period: 1994–1998	NR	NR	NR	U.S.	Fair	5

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Nichols, 2007 (24)	**Women aged 20–74 yr in Collaborative Breast Cancer Study** Cases: 1878 breast cancer *in situ,* registry Controls: 8041, community Recruitment period: 1997–2001	1.10	0.99 to 1.25	Age, parity, menopausal status, family history, age at menarche, smoking, state, age at first birth, age at menopause, HRT, weight at age 18, height, weight gain since age 18, education, mammography screening, history of benign breast disease	U.S.	Good	6
Shantakumar, 2007 (25)	**Long Island Breast Cancer Study Project (age NR)** *Premenopausal women* Cases: 468 *in situ* or invasive breast cancer, rapid case ascertainment Controls: 500, community	0.82	0.57 to 1.19	Age	U.S.	Good	1
	Postmenopausal <65 years old Cases: 491 *in situ* or invasive breast cancer, registry, rapid case ascertainment Controls: 554, community	0.95	0.74 to 1.22				
	Postmenopausal >65 years old Cases: 519 *in situ* or invasive breast cancer, registry Controls: 439, community Recruitment period: 1996–1997	1.37	1.04 to 1.81				

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Sweeney, 2007 (26)	**Hispanic and non-Hispanic white women ≤64 yr** *All subjects* Cases: 2303 breast cancer, registries Controls: 2513, community *Hispanics only* Cases: 796 breast cancer, registries Controls: 919, community *Non-Hispanic Whites* Cases: 1522 breast cancer, registries Controls: 1586, community Recruitment period: 1999–2004	1.08 1.08 1.10	0.94 to 1.24 0.90 to 1.29 0.88 to 1.37	Age, parity, menopausal status, family history, study center, education, alcohol, language acculturation, years since last birth, use of contraception injections and HRT	U.S.	Good	1
Figueiredo, 2008 (27)	**Women <55 yr in Women's Environment, and Radiation Epidemiology Study** *Women with history of unilateral breast cancer* Cases: 708 asynchronous bilateral breast cancer, registry Controls: 1399 unilateral breast cancer only, registry Recruitment period: 1985–2000	0.88	0.67 to 1.16	Parity, menopausal status, family history, age at menarche, counter-matching sampling, age at diagnosis of first breast cancer, family history of breast cancer in a first degree relative, histology, stage, chemotherapy, hormonal therapy, radiation therapy	U.S.	Fair	7

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Lee, 2008 (28)	**Women aged 20–49 yr in Women's Learning the Influence of Family and Environment Study**			Age, race, parity, family history, education, Ashkenazi Jewish	U.S.	Good	
	Cases: 94, breast cancer and BRCA1/2 carrier, registry Controls: 444 BRCA1/2 unknown, community	0.68	0.33 to 1.38				3
	Cases: 1375 breast cancer, not BRCA1/2 carrier, registry Controls: 444 BRCA1/2 unknown, community	0.81	0.57 to 1.14				1
	Recruitment period: 1998–2003						
Nyante, 2008 (29)	**Women aged 20–44 yr in Women's Interview Study of Health**			Age, site, frequency of pap smears	U.S.	Fair	4
	Ductal cancer Cases: 1164 invasive or *in situ* cancer, rapid reporting system Controls: 1501, community	1.21	1.01 to 1.45				
	Lobular cancer Cases: 100, invasive or *in situ* cancer, rapid reporting system Controls: 1501, community	1.10	0.68 to 1.78				
	Recruitment period: 1990–1992						
Phillips, 2009 (30)	**Women aged 20–74 yr in Carolina Breast Cancer Study**			Age, race	U.S.	Fair	1
	Cases: 1808 invasive breast cancer, registry Controls: 1564, community	1.11	0.94 to 1.32				
	Cases: 446 *in situ* cancer, registry Controls: 458, community	1.11	0.80 to 1.53				
	Recruitment period: 1993–2001						

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Rosenberg, 2009 (31)	**Women aged 25–69 yr in Case-Control Surveillance Study** *Cases: all invasive cancers* Cases: 907 breast cancer, hospital Controls: 1711, hospital *Age <50* Cases: 431 breast cancer, hospital Controls: 939, hospital *Age ≥50* Cases: 476 breast cancer, hospital Controls: 772, no breast cancer, hospital *Black women* Cases: 176 breast cancer, hospital Controls: 559, hospital *White women* Cases: 731 breast cancer, hospital Controls: 1152, hospital Recruitment period: 1976–1996	NR	NR	NA	U.S.	Fair	5
Figueiredo, 2010 (32)	**Women <55 yr in Women's Environment, and Radiation Epidemiology Study** *BRCA1 carriers (cases and controls)* Cases: 67 contralateral breast cancer, registry Controls: 42 unilateral breast cancer, registry *BRCA2 carriers (cases and controls)* Cases: 41 contralateral breast cancer, registry Controls: 31 contralateral breast cancer, registry Recruitment period: 1985–2000	0.82 2.38	0.21 to 3.13 0.72 to 7.83	Age	U.S.	Fair	7

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Lumachi, 2010 (33)	**Women who underwent curative surgery for breast cancer** *Postmenopausal women* Cases: 238 breast cancer, surgically treated Controls: 255, mammography screening Mean age of cases at diagnosis: 62 yr (SD 10) Recruitment period: NR	2.06	1.14 to 3.70	Unadjusted	Italy	Fair	1
Ma, 2010 (34)	**White or African-American women aged 35–64 yr** Cases: 335 triple-negative breast cancer, registries Controls: 2015, community	0.93	0.74 to 1.17	Age, race, parity, menopausal status, BMI, family history, age at menarche, study site, education	U.S.	Good	8
	Cases: 97 ER-/PR/HER2+ breast cancer, registries Controls: 2015, community	1.00	0.72 to 1.39				
	Cases: 645 luminal A breast cancer, registries Controls: 2015, community	1.21	0.69 to 2.11				
	Cases: 120 luminal B breast cancer, registries Controls: 2015, community	1.23	0.73 to 2.10				
	Recruitment period: 2000–2003						
Xu, 2011 (35)	**Women aged 25–65 yr in Shanghai Breast Cancer Study** Cases: 2073 breast cancer, hospitals and registry Controls: 2084, resident registry Recruitment periods: 1996–1998; 2002–2005	0.98	0.83 to 1.15	Age, parity, menopausal status, BMI, family history, age at menarche, education	China	Good	1

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Marchbanks, 2012 (36)	**White or black women aged 35–64 yr** Cases: 2282, registries Controls: 2424, community Recruitment period: 1994–1998	NR	NR	NA	U.S.	Good	5
Urban, 2012 (37)	**Black South African women aged 18–79 yr** Cases: 256, hospital Controls: 156, hospital Recruitment period: 1995–2006	1.28	1.0 to 1.64	Age, parity, smoking, year of diagnosis, education, alcohol consumption, sexual partners, urban/rural residence, province of birth	South Africa	Good	1
Cohort							
Grabrick, 2000 (38)	**Family members of women aged 21–88 yr diagnosed with breast cancer between 1944 and 1952** Exposed: 3156 Unexposed: 2994 Recruitment period: 1991–1996	1.4	1.0 to 2.0	Age, birth cohort, class effect of family	U.S.	Good	2
Kumle, 2002 (39)	**Women aged 30–49 yr in prospective cohort study** Exposed: 74,856 Unexposed: 28,171 Recruitment period: 1991–1992	1.3	1.1 to 1.5	Age, parity, menopausal status, BMI, family history, age at menarche, breastfeeding , age at first birth, HRT use, region, BMI times menopausal status	Norway, Sweden	Good	1
Dumeaux, 2003 (40)	**Women aged 30–70 yr in Norwegian Women and Cancer Study** Exposed: 49,322 Unexposed: 37,690 Recruitment period: 1991–1997	1.25	1.07 to1.46	Age, parity, menopausal status, BMI, family history, age at menarche, geographic area, invitation of breast cancer screening, age at first birth, HRT use, alcohol consumption	Norway	Fair	1

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Dumeaux, 2005 (41)	**E3N-EPIC Cohort women aged 40–60 yr** Exposed: 28,251 Unexposed: 40,419 Recruitment period: 1990	0.91	0.81 to 1.03	Parity, BMI, family history, age at menarche, frequency of pap smears, history of benign breast disease, alcohol consumption, time since menopause	France	Fair	1
Silvera, 2005 (42)	**Women aged 40–59 yr in Canadian National Breast Screening Study** *Women with first- or second-degree relatives with breast cancer* Exposed: 962 Unexposed: 745	0.88	0.73 to 1.07	Age, parity, menopausal status, BMI, age at menarche, alcohol, history of breast disease, age at first birth, HRT use, study center, randomization group	Canada	Good	2
	Women with first-degree relatives with breast cancer Exposed: 433 Unexposed: 362	1.03	0.78 to 1.38				
	Women with second-degree relatives with breast cancer Exposed: 414 Unexposed: 284	0.74	0.54 to 1.00				
	Recruitment period: 1980–1985						
Vessey, 2006 (43)	**Women aged 25–39 yr at study entry in Oxford Family Planning Association Contraceptive Study** Exposed: 301,000 person-years Unexposed: 187,000 person-years	1.0	0.8 to 1.1	Age, parity, BMI, breastfeeding, social class, height, age at first term pregnancy, age at first marriage	UK	Good	1
	Recruitment period: 1968–1974						
Brohet, 2007 (44)	**Women aged 19–74 yr in International BRCA1/2 Carrier Cohort Study** Exposed: 21,569 person-years Unexposed: 43,611 person-years	1.47	1.16 to 1.87	Age, parity, family clustering, history of oophorectomy before right censoring	UK, France, Netherlands	Fair	3
	Recruitment period: NR						

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Hannaford, 2007 (45)	**Royal College of General Practitioner's Oral Contraception Study** Exposed: 744,000 person-years Unexposed: 339,000 person-years Mean age at entry: 29 yr (SD 6.6) Recruitment period: 1968–NR	0.98	0.87 to 1.10	Age, parity, smoking, social status; ever use HRT	UK	Fair	1
Lund, 2007 (46)	**Women aged 34–70 yr in Norwegian Women and Cancer Study** Exposed: 11,371 Unexposed: 18,747 Recruitment period: 1991–1997	1.33	1.11 to 1.59	Parity, BMI, family history, age at menarche, mammography, age at first delivery	Norway	Good	1
Dorjgochoo, 2009 (47)	**Women aged 40–70 yr in Shanghai Women's Health Study** Exposed: 12,957 Unexposed: 15,557 Recruitment period: 1997–2000	1.05	0.84 to1 .31	Age, parity, menopausal status, BMI, family history, age at menarche, smoking, breastfeeding , education, physical activity, other contraceptive methods	China	Fair	1
Rosenblatt, 2009 (48)	**Textile Workers aged 30–64 yr in Shanghai** Exposed: 352,695 person-years Unexposed: 2,057,377 person-years Recruitment period: 1989–1991	0.9	0.78 to 1.03	Age, parity	China	Poor	1
Hunter, 2010 (49)	**Nurses' Health Study II of women aged 24–43 yr at study entry** Exposed: 1,070,386 person-years Unexposed: 176,581 person-years Recruitment period: 1989–2001	NR	NR	NA	U.S.	Good	4

Study[a]	Study Details	OR[b]	95% CI	Covariates	Region	Study Quality	Meta-Analysis Code[c]
Rosenberg, 2010 (50)	**Women aged 21–69 yr in Black Women's Health Study** Exposed: 445,824 person-years Unexposed: 128,768 person-years			Age, parity, BMI, family history, age at menarche, education, age at first birth, age at menopause, HRT, exercise, alcohol, questionnaire cycle	U.S.	Fair	8
	ER+/PR+ receptor status Cases: 284	IRR=1.11	0.86 to 1.42				
	ER+/PR- receptor status Cases: 80	IRR=0.97	0.61 to1.54				
	ER-/PR- receptor status Cases: 46	IRR=1.65	1.19 to 2.30				
	Recruitment period: 1995						
Bernholtz, 2011 (51)	**Jewish women at high risk of developing breast or ovarian cancer**			Age at menarche, breastfeeding, year of birth	Israel	Fair	3
	BRCA1 or BRCA2 carriers Exposed: 403 Unexposed: 373	1.84	1.47 to 2.31				
	BRCA1 carriers Exposed: 309 Unexposed: 182	1.72	1.31 to 2.25				
	BRCA2 carriers Exposed: 136 Unexposed: 72	2.07	1.34 to 3.20				
	Recruitment period: 1996–2010						
Pooled							
Dolle, 2009 (52)	**Women aged 21–45 yr in Seattle-Puget Sound** Cases: 897 with invasive cancer; 187 with triple negative cancer; registries Controls: 1569, not reported Recruitment periods: 1983–1990; 1990–1992	1.3 (all subjects) 2.5 (triple-negative subjects)	1.0 to 1.7 1.4 to 4.3	Age, family history, breastfeeding history, oral contraceptive duration	U.S.	Fair	8

BMI, body mass index; CI, confidence interval; DMV, department of motor vehicles; ER, estrogen receptor; HRT, hormone replacement therapy; IRR, incidence rate ratio; NR, not reported; NZ, New Zealand; OC, oral contraceptive; OR, odds ratio; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results registry; UK, United Kingdom; U.S., United States; yr, year/years.

[a] Study identifies the primary abstracted article. For details about the relationships between companion studies and articles, refer to Appendix C of the full AHRQ report.

[b] Odds ratios for meta-analysis of ever versus never OC use.

[c] Meta-analysis code: 1= Included in meta-analysis; 2 = Excluded due to family history of breast cancer; 3 = Excluded due to BRCA mutation carriers; 4 = Excluded due to age at diagnosis ≤45 years; 5 = Excluded due to overall ever versus never OR not reported or not calculable; 6 = Excluded due to cancer in situ only; 7 = Excluded due to all cases and controls having breast cancer; 8 = Excluded due to ER/PR/HER2 subtypes; 9 = Excluded due to data are subset of Shanghai Breast Cancer Study(35); 10 = Excluded due to targeting certain subtypes of cancer only.

References for Supplementary Table 1

1. Shapiro S, Rosenberg L, Hoffman M, Truter H, Cooper D, Rao S, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol 2000;151:396-403.
2. Van Hoften C, Burger H, Peeters PH, Grobbee DE, Van Noord PA, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000;87:591-4.
3. Gomes AL, Guimaraes MD, Gomes CC, Chaves IG, Gobbi H, Camargos AF. Risk factors for breast cancer among pre- or post-menopausal women in Belo Horizonte, Brazil. Gynecol Obstet Invest 2001;52:173-9.
4. Moorman PG, Millikan RC, Newman B. Oral contraceptives and breast cancer among African-American women and white women. J Natl Med Assoc 2001;93:329-34.
5. Heimdal K, Skovlund E, Moller P. Oral contraceptives and risk of familial breast cancer. Cancer Detect Prev 2002;26:23-7.
6. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-32.
7. Narod SA, Dube MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002;94:1773-9.
8. Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer 2002;98:604-8.

9. Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003;14:151-60.

10. Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003;88:50-7.

11. Newcomer LM, Newcomb PA, Trentham-Dietz A, Longnecker MP, Greenberg ER. Oral contraceptive use and risk of breast cancer by histologic type. Int J Cancer 2003;106:961-4.

12. Norman SA, Berlin JA, Weber AL, Strom BL, Daling JR, Weiss LK, et al. Combined effect of oral contraceptive use and hormone replacement therapy on breast cancer risk in postmenopausal women. Cancer Causes Control 2003;14:933-43.

13. Suter NM, Malone KE, Daling JR, Doody DR, Ostrander EA. Androgen receptor (CAG)n and (GGC)n polymorphisms and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol Biomarkers Prev 2003;12:127-35.

14. Wrensch M, Chew T, Farren G, Barlow J, Belli F, Clarke C, et al. Risk factors for breast cancer in a population with high incidence rates. Breast Cancer Res 2003;5:R88-102.

15. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT, et al. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004;13:1308-15.

16. Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 2005;41:2312-20.

17. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2005;14:350-6.

18. Gronwald J, Byrski T, Huzarski T, Cybulski C, Sun P, Tulman A, et al. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006;95:105-9.

19. Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, et al. BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 2006;15:1863-70.

20. Ma H, Bernstein L, Ross RK, Ursin G. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: Results from a case-control and a case-case comparison. Breast Cancer Research 2006;8.

21. Rosenberg LU, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman PW. Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.

22. Faheem M, Khurram M, Jafri IA, Mehmood H, Hasan Z, Iqbal GS, et al. Risk factors for breast cancer in patients treated at NORI Hospital, Islamabad. J Pak Med Assoc 2007;57:242-5.

23. Folger SG, Marchbanks PA, McDonald JA, Bernstein L, Ursin G, Berlin JA, et al. Risk of breast cancer associated with short-term use of oral contraceptives. Cancer Causes Control 2007;18:189-98.

24. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Hampton JM, Newcomb PA. Oral contraceptive use and risk of breast carcinoma in situ. Cancer Epidemiol Biomarkers Prev 2007;16:2262-8.

25. Shantakumar S, Terry MB, Paykin A, Teitelbaum SL, Britton JA, Moorman PG, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007;165:1187-98.

26. Sweeney C, Giuliano AR, Baumgartner KB, Byers T, Herrick JS, Edwards SL, et al. Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women. Int J Cancer 2007;121:2517-23.

27. Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton-Culver H, et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. J Clin Oncol 2008;26:1411-8.

28. Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE, et al. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 2008;17:3170-8.

29. Nyante SJ, Gammon MD, Malone KE, Daling JR, Brinton LA. The association between oral contraceptive use and lobular and ductal breast cancer in young women. Int J Cancer 2008;122:936-41.

30. Phillips LS, Millikan RC, Schroeder JC, Barnholtz-Sloan JS, Levine BJ. Reproductive and hormonal risk factors for ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2009;18:1507-14.

31. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169:473-9.

32. Figueiredo JC, Haile RW, Bernstein L, Malone KE, Largent J, Langholz B, et al. Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat 2010;120:175-83.

33. Lumachi F, Frigo AC, Basso U, Tombolan V, Ermani M. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. Menopause 2010;17:524-8.

34. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, Spirtas R, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010;70:575-87.

35. Xu WH, Shu XO, Long J, Lu W, Cai Q, Zheng Y, et al. Relation of FGFR2 genetic polymorphisms to the association between oral contraceptive use and the risk of breast cancer in Chinese women. Am J Epidemiol 2011;173:923-31.

36. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012;85:342-350.

37. Urban M, Banks E, Egger S, Canfell K, O'Connell D, Beral V, et al. Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. PLoS Med 2012;9:e1001182.

38. Grabrick DM, Hartmann LC, Cerhan JR, Vierkant RA, Therneau TM, Vachon CM, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000;284:1791-8.

39. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.

40. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 2003;105:844-50.

41. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control 2005;16:537-44.

42. Silvera SA, Miller AB, Rohan TE. Oral contraceptive use and risk of breast cancer among women with a family history of breast cancer: a prospective cohort study. Cancer Causes Control 2005;16:1059-63.

43. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer 2006;95:385-9.

44. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 2007;25:3831-6.

45. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ 2007;335:651.

46. Lund E, Bakken K, Dumeaux V, Andersen V, Kumle M. Hormone replacement therapy and breast cancer in former users of oral contraceptives--The Norwegian Women and Cancer study. Int J Cancer 2007;121:645-8.

47. Dorjgochoo T, Shu XO, Li HL, Qian HZ, Yang G, Cai H, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2009;124:2442-9.

48. Rosenblatt KA, Gao DL, Ray RM, Nelson ZC, Wernli KJ, Li W, et al. Oral contraceptives and the risk of all cancers combined and site-specific cancers in Shanghai. Cancer Causes Control 2009;20:27-34.

49. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010;19:2496-502.

50. Rosenberg L, Boggs DA, Wise LA, Adams-Campbell LL, Palmer JR. Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev 2010;19:2073-9.

51. Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon S, Friedman E. Cancer risk in Jewish BRCA1 and BRCA2 mutation carriers: Effects of oral contraceptive use and parental origin of mutation. Breast Cancer Research and Treatment 2011;129:557-563.

52. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-66.